Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report

Kerrisdale Capital is at it again, this time revealing a short position in struggling biotech firm Altimmune (NASDAQ:ALT). The acclaimed short seller has just released a damning short report on the company, saying that its only viable product, a weight-loss drug, has little chance of commercial success and will “bomb” in upcoming Phase 3 trials. As of this writing, ALT stock is down roughly 20%.Altimmune has been struggling for months, failing to demonstrate any real growth. Positive clinical trial results ...